Hope for duchenne: Five-Year cell therapy trial aims to slow progression
NCT ID NCT04428476
Summary
This study is a long-term follow-up for patients who completed a previous trial for Duchenne muscular dystrophy. It aims to provide continued access to an experimental cell therapy called deramiocel and gather more data on its long-term safety and whether it helps slow the loss of arm and hand function and protects heart health. About 13 participants will receive intravenous infusions every three months for up to five years or longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
University of California, Davis
Sacramento, California, 95817, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.